174 related articles for article (PubMed ID: 31882602)
21. Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120.
Gift SK; McFadden K; Zentner IJ; Rajagopal S; Zhang MY; Dimitrov DS; Chaiken IM
Biochemistry; 2011 Apr; 50(14):2769-79. PubMed ID: 21417283
[TBL] [Abstract][Full Text] [Related]
22. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.
Kong L; Lee JH; Doores KJ; Murin CD; Julien JP; McBride R; Liu Y; Marozsan A; Cupo A; Klasse PJ; Hoffenberg S; Caulfield M; King CR; Hua Y; Le KM; Khayat R; Deller MC; Clayton T; Tien H; Feizi T; Sanders RW; Paulson JC; Moore JP; Stanfield RL; Burton DR; Ward AB; Wilson IA
Nat Struct Mol Biol; 2013 Jul; 20(7):796-803. PubMed ID: 23708606
[TBL] [Abstract][Full Text] [Related]
23. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
Wilkinson RA; Piscitelli C; Teintze M; Cavacini LA; Posner MR; Lawrence CM
J Virol; 2005 Oct; 79(20):13060-9. PubMed ID: 16189008
[TBL] [Abstract][Full Text] [Related]
24. AIDS/HIV. Converging on an HIV vaccine.
Korber B; Gnanakaran S
Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189
[No Abstract] [Full Text] [Related]
25. Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.
Cale EM; Gorman J; Radakovich NA; Crooks ET; Osawa K; Tong T; Li J; Nagarajan R; Ozorowski G; Ambrozak DR; Asokan M; Bailer RT; Bennici AK; Chen X; Doria-Rose NA; Druz A; Feng Y; Joyce MG; Louder MK; O'Dell S; Oliver C; Pancera M; Connors M; Hope TJ; Kepler TB; Wyatt RT; Ward AB; Georgiev IS; Kwong PD; Mascola JR; Binley JM
Immunity; 2017 May; 46(5):777-791.e10. PubMed ID: 28514685
[TBL] [Abstract][Full Text] [Related]
26. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.
Zwick MB; Komori HK; Stanfield RL; Church S; Wang M; Parren PW; Kunert R; Katinger H; Wilson IA; Burton DR
J Virol; 2004 Mar; 78(6):3155-61. PubMed ID: 14990736
[TBL] [Abstract][Full Text] [Related]
27. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Scheid JF; Mouquet H; Ueberheide B; Diskin R; Klein F; Oliveira TY; Pietzsch J; Fenyo D; Abadir A; Velinzon K; Hurley A; Myung S; Boulad F; Poignard P; Burton DR; Pereyra F; Ho DD; Walker BD; Seaman MS; Bjorkman PJ; Chait BT; Nussenzweig MC
Science; 2011 Sep; 333(6049):1633-7. PubMed ID: 21764753
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.
Ofek G; Zirkle B; Yang Y; Zhu Z; McKee K; Zhang B; Chuang GY; Georgiev IS; O'Dell S; Doria-Rose N; Mascola JR; Dimitrov DS; Kwong PD
J Virol; 2014 Mar; 88(5):2426-41. PubMed ID: 24335316
[TBL] [Abstract][Full Text] [Related]
29. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
30. CDR-H3 loop ensemble in solution - conformational selection upon antibody binding.
Fernández-Quintero ML; Kraml J; Georges G; Liedl KR
MAbs; 2019; 11(6):1077-1088. PubMed ID: 31148507
[TBL] [Abstract][Full Text] [Related]
31. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.
Ofek G; McKee K; Yang Y; Yang ZY; Skinner J; Guenaga FJ; Wyatt R; Zwick MB; Nabel GJ; Mascola JR; Kwong PD
J Virol; 2010 Mar; 84(6):2955-62. PubMed ID: 20042512
[TBL] [Abstract][Full Text] [Related]
32. Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.
Spurrier B; Sampson JM; Totrov M; Li H; O'Neal T; Williams C; Robinson J; Gorny MK; Zolla-Pazner S; Kong XP
Structure; 2011 May; 19(5):691-9. PubMed ID: 21565703
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.
Clark KR; Walsh ST
Protein Sci; 2009 Dec; 18(12):2429-41. PubMed ID: 19785005
[TBL] [Abstract][Full Text] [Related]
34. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
Thenin S; Roch E; Samleerat T; Moreau T; Chaillon A; Moreau A; Barin F; Braibant M
J Gen Virol; 2012 Jul; 93(Pt 7):1495-1505. PubMed ID: 22492917
[TBL] [Abstract][Full Text] [Related]
35. Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.
Kirby KA; Ong YT; Hachiya A; Laughlin TG; Chiang LA; Pan Y; Moran JL; Marchand B; Singh K; Gallazzi F; Quinn TP; Yoshimura K; Murakami T; Matsushita S; Sarafianos SG
FASEB J; 2015 Jan; 29(1):70-80. PubMed ID: 25351987
[TBL] [Abstract][Full Text] [Related]
36. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
Torán JL; Sánchez-Pulido L; Kremer L; del Real G; Valencia A; Martínez-A C
Eur J Immunol; 2001 Jan; 31(1):128-37. PubMed ID: 11169446
[TBL] [Abstract][Full Text] [Related]
37. The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops.
Tsuchiya Y; Mizuguchi K
Protein Sci; 2016 Apr; 25(4):815-25. PubMed ID: 26749247
[TBL] [Abstract][Full Text] [Related]
38. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
39. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.
Doores KJ; Burton DR
J Virol; 2010 Oct; 84(20):10510-21. PubMed ID: 20686044
[TBL] [Abstract][Full Text] [Related]
40. Mutation of Framework Residue H71 Results in Different Antibody Paratope States in Solution.
Fernández-Quintero ML; Kroell KB; Hofer F; Riccabona JR; Liedl KR
Front Immunol; 2021; 12():630034. PubMed ID: 33737932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
